Paul Grayson, Tentarix Biotherapeutics CEO

Gilead dish­es out $66M for San Diego biotech's 'ten­ta­cles' in can­cer, in­flam­ma­tion

Gilead will pony up $66 mil­lion in an up­front pay­ment and eq­ui­ty in­vest­ment to col­lab­o­rate with Ten­tar­ix Bio­ther­a­peu­tics on bi­o­log­ics for in­flam­ma­to­ry dis­eases and on­col­o­gy, the com­pa­nies said Tues­day morn­ing.

San Diego-based Ten­tar­ix could re­ceive up to an­oth­er $240 mil­lion if Gilead elects to ac­quire three of the biotech’s sub­sidiaries that house the on­col­o­gy and in­flam­ma­to­ry dis­ease pro­grams in­clud­ed in the pact, the part­ners said. That fig­ure would be split even­ly across the three pro­grams, which use the start­up’s so-called Ten­ta­cles plat­form.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA